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Abstract
We have established an Adriamycin (ADM) -resistant small cell lung cancer (SCLC) cell line,
SBC-3/ADM100, which shows multifactorial mechanisms of resistance to ADM, such as overex-
pression of P-glycoprotein, an enhanced detoxifying system and a decrease in topoisomerase II
activity. In the present study, we confirmed that SBC-3/ADM 100 showed collateral sensitivity
to methotrexate and TNP-351, a new antifolate, though this cell line showed a typical multidrug
resistance (MDR) pattern. We also demonstrated a faster uptake and higher accumulation (1.3-
fold) of TNP-351 in the SBC-3/ADM100 cells than those in the parent SBC-3 cells. These results
explain one of the mechanisms for collateral sensitivity in the resistant cells. Furthermore, this cell
line was found to have no cross-resistance to edatrexate and minimal cross-resistance to trimetrex-
ate, 254-S (cisplatin analog), 5-fluorouracil and 4-hydroperoxyifosfamide. These drugs will have
clinical importance in patients with SCLC who were previously treated with an ADM-containing
regimen. Thus, antifolates, especially TNP-351 and edatrexate, can be expected to eradicate resid-
ual multidrug resistant SCLC cells selected by ADM.
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